{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:29:48Z","timestamp":1791660588972,"version":"4.3.4"},"reference-count":61,"publisher":"Harborside Press, LLC","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Previous studies have operationalized the NCCN list of high-risk medications in older adults into a measurable tool known as the Geriatric Oncology Potentially Inappropriate Medications (GO-PIMs) scale. The current study aims to evaluate the ability of GO-PIMs to identify high-risk medications and their impact on patients with both solid and liquid tumors managed in a large national health care system. <jats:bold>Methods:<\/jats:bold> We performed a retrospective cohort study using data from the national Veterans Affairs (VA) Cancer Registry and electronic health records, including all veterans newly diagnosed with a solid or liquid malignancy from 2000 to 2022. The number of GO-PIMs for each patient was determined from outpatient pharmacy prescriptions filled in the 90 days preceding the initial cancer diagnosis (the index date). We assessed the association of PIMs with baseline frailty\u2014measured using the electronic Veterans Affairs Frailty Index (VA-FI) and categorized as nonfrail (\u22640.2), mildly frail (&gt;0.2\u20130.3), or moderate-to-severely frail (&gt;0.3)\u2014and with unplanned hospitalization and mortality during follow-up, using multivariable models adjusted for age, gender, cancer type and stage, Charlson comorbidity index score, and socioeconomic factors. <jats:bold>Results:<\/jats:bold> Among 388,113 patients with newly diagnosed cancer (median age, 69.3 years [IQR, 62.8\u201376.7]; most common cancer types: prostate [21.5%], lung [23.7%], and gastrointestinal [20.5%]), GO-PIMs were prevalent, with 38% patients receiving \u22651 GO-PIM. Each additional GO-PIM was associated with a 66% increase in the odds of being mildly or moderate-to-severely frail at diagnosis, after adjusting for all covariates (ordinal regression adjusted odds ratio, 1.66; 95% CI, 1.65\u20131.67). Each additional GO-PIM was also associated with a higher hazard of unplanned hospitalization (Cox regression adjusted hazard ratio [aHR], 1.08; 95% CI, 1.07\u20131.08) and death (Cox regression aHR, 1.07; 95% CI, 1.06\u20131.07), after adjusting for frailty and all covariates. <jats:bold>Conclusions:<\/jats:bold> An increasing number of PIMs, as identified by the GO-PIMs scale, was independently associated with greater risk of frailty at diagnosis, unplanned hospitalization during follow-up, and mortality among patients treated within a large national health care system.<\/jats:p>","DOI":"10.6004\/jnccn.2025.7051","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T12:25:39Z","timestamp":1757507139000},"page":"363-370","source":"Crossref","is-referenced-by-count":4,"title":["Potentially Inappropriate Medications, Frailty, and Outcomes in Patients With Cancer Managed in a National Health Care System"],"prefix":"10.6004","volume":"23","author":[{"given":"Jennifer","family":"La","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, MA"},{"name":"VA Boston Cooperative Studies Program Center, MAVERIC, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"Hshieh","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA"},{"name":"Dana-Farber Cancer Institute, Boston, MA"},{"name":"Brigham and Women\u2019s Hospital, Boston, MA"},{"name":"Hebrew SeniorLife and Marcus Institute for Aging Research, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahid","family":"Hamparsumian","sequence":"additional","affiliation":[{"name":"Duke University, Durham Health System, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zwolinski","sequence":"additional","affiliation":[{"name":"VA Boston Cooperative Studies Program Center, MAVERIC, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jameson","family":"Wood","sequence":"additional","affiliation":[{"name":"VA Boston Healthcare System, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuri","family":"Dharne","sequence":"additional","affiliation":[{"name":"VA Boston Cooperative Studies Program Center, MAVERIC, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"Gaziano","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA"},{"name":"VA Boston Cooperative Studies Program Center, MAVERIC, Boston, MA"},{"name":"VA Boston Healthcare System, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary T.","family":"Brophy","sequence":"additional","affiliation":[{"name":"VA Boston Cooperative Studies Program Center, MAVERIC, Boston, MA"},{"name":"Boston University School of Medicine, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhan V.","family":"Do","sequence":"additional","affiliation":[{"name":"VA Boston Cooperative Studies Program Center, MAVERIC, Boston, MA"},{"name":"Boston University School of Medicine, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA"},{"name":"Dana-Farber Cancer Institute, Boston, MA"},{"name":"VA Boston Healthcare System, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane A.","family":"Driver","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA"},{"name":"Brigham and Women\u2019s Hospital, Boston, MA"},{"name":"New England Geriatrics Research, Education, and Clinical Center, VA Boston Healthcare System, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Abel","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA"},{"name":"Dana-Farber Cancer Institute, Boston, MA"},{"name":"Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathanael R.","family":"Fillmore","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA"},{"name":"VA Boston Cooperative Studies Program Center, MAVERIC, Boston, MA"},{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clark","family":"DuMontier","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA"},{"name":"Dana-Farber Cancer Institute, Boston, MA"},{"name":"Brigham and Women\u2019s Hospital, Boston, MA"},{"name":"New England Geriatrics Research, Education, and Clinical Center, VA Boston Healthcare System, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Cancer","first-page":"1096","article-title":"Association of polypharmacy and potential drug-drug interactions with adverse treatment outcomes in older adults with advanced cancer","volume":"129","author":"Mohamed MR","year":"2023","unstructured":"Mohamed MR, Mohile SG, Juba KM,  Association of polypharmacy and potential drug-drug interactions with adverse treatment outcomes in older adults with advanced cancer. Cancer 2023;129:1096\u20131104."},{"key":"B2","series-title":"J Geriatr Oncol","first-page":"307","article-title":"Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy","volume":"5","author":"Popa MA","year":"2014","unstructured":"Popa MA, Wallace KJ, Brunello A,  Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy. J Geriatr Oncol 2014;5:307\u2013314."},{"key":"B3","series-title":"J Gerontol A Biol Sci Med Sci","first-page":"989","article-title":"Polypharmacy among adults aged 65 years and older in the United States: 1988\u20132010","volume":"70","author":"Charlesworth CJ","year":"2015","unstructured":"Charlesworth CJ, Smit E, Lee DS,  Polypharmacy among adults aged 65 years and older in the United States: 1988\u20132010. J Gerontol A Biol Sci Med Sci 2015;70:989\u2013995."},{"key":"B4","series-title":"Oncologist","first-page":"e94","article-title":"Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: a systematic review and meta\u2010analysis","volume":"25","author":"Mohamed MR","year":"2020","unstructured":"Mohamed MR, Ramsdale E, Loh KP,  Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: a systematic review and meta\u2010analysis. Oncologist 2020;25:e94\u2013108."},{"key":"B5","series-title":"J Natl Compr Canc Netw","first-page":"1006","article-title":"NCCN Guidelines Insights: Older Adult Oncology, Version 1.2021","volume":"19","author":"Dotan E","year":"2021","unstructured":"Dotan E, Walter LC, Browner IS,  NCCN Guidelines Insights: Older Adult Oncology, Version 1.2021. J Natl Compr Canc Netw 2021;19:1006\u20131019."},{"key":"B6","series-title":"J Clin Oncol","first-page":"4293","article-title":"Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update","volume":"41","author":"Dale W","year":"2023","unstructured":"Dale W, Klepin HD, Williams GR,  Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update. J Clin Oncol 2023;41:4293\u20134312."},{"key":"B7","article-title":"Medicare and Medicaid programs and the Children\u2019s Health Insurance Program; hospital inpatient prospective payment systems for acute care hospitals and the long-term care hospital prospective payment system and policy changes and fiscal year 2025 rates; quality programs requirements; and other policy changes","unstructured":"Centers for Medicare & Medicaid Services. Medicare and Medicaid programs and the Children\u2019s Health Insurance Program; hospital inpatient prospective payment systems for acute care hospitals and the long-term care hospital prospective payment system and policy changes and fiscal year 2025 rates; quality programs requirements; and other policy changes. Accessed June 2, 2025. Available at: https:\/\/www.federalregister.gov\/documents\/2024\/08\/28\/2024-17021\/medicare-and-medicaid-programs-and-the-childrens-health-insurance-program-hospital-inpatient"},{"key":"B8","series-title":"Support Care Cancer","first-page":"674.","article-title":"Effect of polypharmacy and potentially inappropriate medications on physical functional decline among older adults with advanced cancer receiving systemic treatment","volume":"32","author":"Mohamed MR","year":"2024","unstructured":"Mohamed MR, Juba K, Awad H,  Effect of polypharmacy and potentially inappropriate medications on physical functional decline among older adults with advanced cancer receiving systemic treatment. Support Care Cancer 2024;32:674."},{"key":"B9","series-title":"J Gerontol A Biol Sci Med Sci","first-page":"1044","article-title":"Systematic review and meta-analysis on the associations of polypharmacy and potentially inappropriate medication with adverse outcomes in older cancer patients","volume":"76","author":"Chen LJ","year":"2021","unstructured":"Chen LJ, Trares K, Laetsch DC,  Systematic review and meta-analysis on the associations of polypharmacy and potentially inappropriate medication with adverse outcomes in older cancer patients. J Gerontol A Biol Sci Med Sci 2021;76:1044\u20131052."},{"key":"B10","series-title":"JCO Oncol Pract","first-page":"336","article-title":"How is geriatric assessment used in clinical practice for older adults with cancer? A survey of cancer providers by the American Society of Clinical Oncology","volume":"17","author":"Dale W","year":"2021","unstructured":"Dale W, Williams GR, R. MacKenzie A,  How is geriatric assessment used in clinical practice for older adults with cancer? A survey of cancer providers by the American Society of Clinical Oncology. JCO Oncol Pract 2021;17:336\u2013344."},{"key":"B11","series-title":"JCO Oncol Pract","first-page":"e1081","article-title":"The use and knowledge of validated geriatric assessment instruments among US community oncologists","volume":"18","author":"Gajra A","year":"2022","unstructured":"Gajra A, Jeune-Smith Y, Fortier S,  The use and knowledge of validated geriatric assessment instruments among US community oncologists. JCO Oncol Pract 2022;18:e1081\u20131090."},{"key":"B12","series-title":"J Natl Compr Canc Netw","first-page":"915","article-title":"Association of polypharmacy and potentially inappropriate medications with frailty among older adults with blood cancers","volume":"20","author":"Hshieh TT","year":"2022","unstructured":"Hshieh TT, DuMontier C, Jaung T,  Association of polypharmacy and potentially inappropriate medications with frailty among older adults with blood cancers. J Natl Compr Canc Netw 2022;20:915\u2013923.e5."},{"key":"B13","series-title":"Nurs Adm Q","first-page":"311","article-title":"The Veterans Affairs\u2019s Corporate Data Warehouse: uses and implications for nursing research and practice","volume":"39","author":"Price LE","year":"2015","unstructured":"Price LE, Shea K, Gephart S. The Veterans Affairs\u2019s Corporate Data Warehouse: uses and implications for nursing research and practice. Nurs Adm Q 2015;39:311\u2013318."},{"key":"B14","series-title":"Mil Med","first-page":"e1883","article-title":"Cancer incidence among patients of the U.S. Veterans Affairs health care system: 2010 update","volume":"182","author":"Zullig LL","year":"2017","unstructured":"Zullig LL, Sims KJ, McNeil R,  Cancer incidence among patients of the U.S. Veterans Affairs health care system: 2010 update. Mil Med 2017;182:e1883\u20131891."},{"key":"B15","series-title":"J Registry Manag","first-page":"21","article-title":"Summary of Veterans Health Administration cancer data sources","volume":"51","author":"Zullig LL","year":"2024","unstructured":"Zullig LL, Jazowski SA, Chawla N,  Summary of Veterans Health Administration cancer data sources. J Registry Manag 2024;51:21\u201328."},{"key":"B16","series-title":"Med Care Res Rev","first-page":"92S","article-title":"Pharmacy data in the VA health care system","volume":"60","author":"Smith MW","year":"2003","unstructured":"Smith MW, Joseph GJ. Pharmacy data in the VA health care system. Med Care Res Rev 2003;60:92S\u2013123S."},{"key":"B17","series-title":"Med Care","first-page":"836","article-title":"Comparison of pharmacy database methods for determining prevalent chronic medication use","volume":"57","author":"Anderson TS","year":"2019","unstructured":"Anderson TS, Jing B, Wray CM,  Comparison of pharmacy database methods for determining prevalent chronic medication use. Med Care 2019;57:836\u2013842."},{"key":"B18","series-title":"J Aging Soc Policy.","article-title":"Provision of home & community based services to veterans by race, rurality, and Neighborhood Deprivation Index","author":"Huan T","unstructured":"Huan T, Intrator O, Kind AJ,  Provision of home & community based services to veterans by race, rurality, and Neighborhood Deprivation Index. J Aging Soc Policy. Published online October 6, 2024. doi:10.1080\/08959420.2024.2402110"},{"key":"B19","series-title":"N Engl J Med","first-page":"2456","article-title":"Making neighborhood-disadvantage metrics accessible \u2013 the Neighborhood Atlas","volume":"378","author":"Kind AJH","year":"2018","unstructured":"Kind AJH, Buckingham WR. Making neighborhood-disadvantage metrics accessible \u2013 the Neighborhood Atlas. N Engl J Med 2018;378:2456\u20132458."},{"key":"B20","series-title":"J Open Source Softw","first-page":"648.","article-title":"An R package for computing comorbidity scores","volume":"3","author":"Gasparini A","year":"2018","unstructured":"Gasparini A. An R package for computing comorbidity scores. J Open Source Softw 2018;3:648."},{"key":"B21","series-title":"J Gerontol A Biol Sci Med Sci","first-page":"1257","article-title":"The burden of frailty among US veterans and its association with mortality","volume":"74","author":"Orkaby AR","year":"2019","unstructured":"Orkaby AR, Nussbaum L, Ho YL,  The burden of frailty among US veterans and its association with mortality. J Gerontol A Biol Sci Med Sci 2019;74:1257\u20131264."},{"key":"B22","series-title":"J Gerontol A Biol Sci Med Sci","first-page":"1318","article-title":"Updating and validating the US Veterans Affairs frailty index: transitioning from ICD-9 to ICD-10","volume":"76","author":"Cheng D","year":"2021","unstructured":"Cheng D, DuMontier C, Yildirim C,  Updating and validating the US Veterans Affairs frailty index: transitioning from ICD-9 to ICD-10. J Gerontol A Biol Sci Med Sci 2021;76:1318\u20131325."},{"key":"B23","series-title":"J Am Geriatr Soc","first-page":"3857","article-title":"Construct validity of the electronic Veterans Affairs Frailty Index against clinician frailty assessment","volume":"71","author":"DuMontier C","year":"2023","unstructured":"DuMontier C, Hennis R, Yilidirim C,  Construct validity of the electronic Veterans Affairs Frailty Index against clinician frailty assessment. J Am Geriatr Soc 2023;71:3857\u20133864."},{"key":"B24","series-title":"Clin Geriatr Med","first-page":"17","article-title":"Frailty defined by deficit accumulation and geriatric medicine defined by frailty","volume":"27","author":"Rockwood K","year":"2011","unstructured":"Rockwood K, Mitnitski A. Frailty defined by deficit accumulation and geriatric medicine defined by frailty. Clin Geriatr Med 2011;27:17\u201326."},{"key":"B25","series-title":"BMC Geriatr","first-page":"24","article-title":"A standard procedure for creating a frailty index","volume":"8","author":"Searle SD","year":"2008","unstructured":"Searle SD, Mitnitski A, Gahbauer EA,  A standard procedure for creating a frailty index. BMC Geriatr 2008;8:24\u201310."},{"key":"B26","series-title":"Age Ageing","first-page":"709","article-title":"Social vulnerability and survival across levels of frailty in the Honolulu-Asia Aging Study","volume":"44","author":"Armstrong JJ","year":"2015","unstructured":"Armstrong JJ, Andrew MK, Mitnitski A,  Social vulnerability and survival across levels of frailty in the Honolulu-Asia Aging Study. Age Ageing 2015;44:709\u2013712."},{"key":"B27","series-title":"Arch Gerontol Geriatr","first-page":"464","article-title":"Frailty in NHANES: comparing the frailty index and phenotype","volume":"60","author":"Blodgett J","year":"2015","unstructured":"Blodgett J, Theou O, Kirkland S,  Frailty in NHANES: comparing the frailty index and phenotype. Arch Gerontol Geriatr 2015;60:464\u2013470."},{"key":"B28","series-title":"Health Rep","first-page":"10","article-title":"Validation of an index to estimate the prevalence of frailty among community-dwelling seniors","volume":"24","author":"Hoover M","year":"2013","unstructured":"Hoover M, Rotermann M, Sanmartin C,  Validation of an index to estimate the prevalence of frailty among community-dwelling seniors. Health Rep 2013;24:10\u201317."},{"key":"B29","series-title":"J Gerontol A Biol Sci Med Sci","first-page":"649","article-title":"Characterizing frailty status in the systolic blood pressure intervention trial","volume":"71","author":"Pajewski NM","year":"2016","unstructured":"Pajewski NM, Williamson JD, Applegate WB,  Characterizing frailty status in the systolic blood pressure intervention trial. J Gerontol A Biol Sci Med Sci 2016;71:649\u2013655."},{"key":"B30","series-title":"Health Serv Outcomes Res Methodol","first-page":"143","article-title":"Using Veterans Affairs Corporate Data Warehouse to identify 30-day hospital readmissions","volume":"18","author":"Vincent BM","year":"2018","unstructured":"Vincent BM, Wiitala WL, Burns JA,  Using Veterans Affairs Corporate Data Warehouse to identify 30-day hospital readmissions. Health Serv Outcomes Res Methodol 2018;18:143\u2013154."},{"key":"B31","series-title":"Popul Health Metr","first-page":"2","article-title":"Accuracy and completeness of mortality data in the Department of Veterans Affairs","volume":"4","author":"Sohn MW","year":"2006","unstructured":"Sohn MW, Arnold N, Maynard C,  Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr 2006;4:2\u20138."},{"key":"B32","series-title":"Lancet","first-page":"1453","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm E","year":"2007","unstructured":"von Elm E, Altman DG, Egger M,  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453\u20131457."},{"key":"B33","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"697","article-title":"Vital signs: changes in opioid prescribing in the United States, 2006-2015","volume":"66","author":"Guy GP","year":"2017","unstructured":"Guy GP, Zhang K, Bohm MK,  Vital signs: changes in opioid prescribing in the United States, 2006-2015. MMWR Morb Mortal Wkly Rep 2017;66:697\u2013704."},{"key":"B34","article-title":"Overdose Prevention: About prescription opioids","unstructured":"U.S. Centers for Disease Control and Prevention. Overdose Prevention: About prescription opioids. Accessed June 2, 2025. Available at: https:\/\/www.cdc.gov\/overdose-prevention\/about\/prescription-opioids.html"},{"key":"B35","series-title":"Pharmacoepidemiol Drug Saf","first-page":"513","article-title":"Decline in opioid prescribing after federal rescheduling of hydrocodone products","volume":"27","author":"Raji MA","year":"2018","unstructured":"Raji MA, Kuo YF, Adhikari D,  Decline in opioid prescribing after federal rescheduling of hydrocodone products. Pharmacoepidemiol Drug Saf 2018;27:513\u2013519."},{"key":"B36","series-title":"N Engl J Med","first-page":"241","article-title":"Trends in opioid analgesic abuse and mortality in the United States","volume":"372","author":"Dart RC","year":"2015","unstructured":"Dart RC, Surratt HL, Cicero TJ,  Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015;372:241\u2013248."},{"key":"B37","series-title":"J Gen Intern Med","first-page":"927","article-title":"Opioid prescribing and opioid risk mitigation strategies in the Veterans Health Administration","volume":"35","author":"Sandbrink F","year":"2020","unstructured":"Sandbrink F, Oliva EM, McMullen TL,  Opioid prescribing and opioid risk mitigation strategies in the Veterans Health Administration. J Gen Intern Med 2020;35:927\u2013934."},{"key":"B38","series-title":"Mayo Clin Proc","first-page":"1632","article-title":"Benzodiazepine use in older adults: dangers, management, and alternative therapies","volume":"91","author":"Markota M","year":"2016","unstructured":"Markota M, Rummans TA, Bostwick JM,  Benzodiazepine use in older adults: dangers, management, and alternative therapies. Mayo Clin Proc 2016;91:1632\u20131639."},{"key":"B39","series-title":"Neurol Int","first-page":"594","article-title":"Benzodiazepines: uses, dangers, and clinical considerations","volume":"13","author":"Edinoff AN","year":"2021","unstructured":"Edinoff AN, Nix CA, Hollier J,  Benzodiazepines: uses, dangers, and clinical considerations. Neurol Int 2021;13:594\u2013607."},{"key":"B40","series-title":"Am J Drug Alcohol Abuse","first-page":"497","article-title":"Biopsychosocial factors and health outcomes associated with cannabis, opioids and benzodiazepines use among older veterans","volume":"47","author":"Kang H","year":"2021","unstructured":"Kang H, Hunniecutt J, Quintero Silva L,  Biopsychosocial factors and health outcomes associated with cannabis, opioids and benzodiazepines use among older veterans. Am J Drug Alcohol Abuse 2021;47:497\u2013507."},{"key":"B41","series-title":"J Am Geriatr Soc","first-page":"98","article-title":"Benzodiazepine use among Medicare, commercially insured, and veteran older adults, 2013\u20132017","volume":"69","author":"Maust DT","year":"2021","unstructured":"Maust DT, Kim HM, Wiechers IR,  Benzodiazepine use among Medicare, commercially insured, and veteran older adults, 2013\u20132017. J Am Geriatr Soc 2021;69:98\u2013105."},{"key":"B42","series-title":"JAMA Intern Med","first-page":"611","article-title":"Addressing the opioid epidemic in the United States: lessons from the Department of Veterans Affairs","volume":"177","author":"Gellad WF","year":"2017","unstructured":"Gellad WF, Good CB, Shulkin DJ. Addressing the opioid epidemic in the United States: lessons from the Department of Veterans Affairs. JAMA Intern Med 2017;177:611\u2013612."},{"key":"B43","series-title":"Med Care","first-page":"171","article-title":"Electronic medical record alert associated with reduced opioid and benzodiazepine coprescribing in high-risk veteran patients","volume":"56","author":"Malte CA","year":"2018","unstructured":"Malte CA, Berger D, Saxon AJ,  Electronic medical record alert associated with reduced opioid and benzodiazepine coprescribing in high-risk veteran patients. Med Care 2018;56:171\u2013178."},{"key":"B44","series-title":"Forensic Toxicol","first-page":"293","article-title":"A review on tramadol toxicity: mechanism of action, clinical presentation, and treatment","volume":"39","author":"Nakhaee S","year":"2021","unstructured":"Nakhaee S, Hoyte C, Dart RC,  A review on tramadol toxicity: mechanism of action, clinical presentation, and treatment. Forensic Toxicol 2021;39:293\u2013310."},{"key":"B45","series-title":"Cancer","first-page":"3978","article-title":"Expert consensus\u2010based guidance on approaches to opioid management in individuals with advanced cancer\u2010related pain and nonmedical stimulant use","volume":"129","author":"Jones KF","year":"2023","unstructured":"Jones KF, Khodyakov D, Han BH,  Expert consensus\u2010based guidance on approaches to opioid management in individuals with advanced cancer\u2010related pain and nonmedical stimulant use. Cancer 2023;129:3978\u20133986."},{"key":"B46","series-title":"CMAJ","first-page":"E352.","article-title":"Tramadol","volume":"185","author":"Young JW","year":"2013","unstructured":"Young JW, Juurlink DN. Tramadol. CMAJ 2013;185:E352."},{"key":"B47","series-title":"BMC Geriatr","first-page":"550.","article-title":"Association of potentially inappropriate medications with prognosis among older patients with non-small cell lung cancer","volume":"24","author":"Ma Z","year":"2024","unstructured":"Ma Z, Xu M, Fu M,  Association of potentially inappropriate medications with prognosis among older patients with non-small cell lung cancer. BMC Geriatr 2024;24:550."},{"key":"B48","series-title":"Res Social Adm Pharm","first-page":"1459","article-title":"Prevalence and factors associated with potentially inappropriate medication use in older medicare beneficiaries with cancer","volume":"16","author":"Feng X","year":"2020","unstructured":"Feng X, Higa GM, Safarudin F,  Prevalence and factors associated with potentially inappropriate medication use in older medicare beneficiaries with cancer. Res Social Adm Pharm 2020;16:1459\u20131471."},{"key":"B49","series-title":"Arch Gerontol Geriatr","first-page":"105087.","article-title":"Potentially inappropriate medication and frailty in older adults: a systematic review and meta-analysis","volume":"114","author":"Ma W","year":"2023","unstructured":"Ma W, Wang H, Wen Z,  Potentially inappropriate medication and frailty in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr 2023;114:105087."},{"key":"B50","series-title":"J Natl Compr Canc Netw","first-page":"267","article-title":"Association of polypharmacy and potentially inappropriate medications with physical functional impairments in older adults with cancer","volume":"19","author":"Mohamed MR","year":"2021","unstructured":"Mohamed MR, Ramsdale E, Loh KP,  Association of polypharmacy and potentially inappropriate medications with physical functional impairments in older adults with cancer. J Natl Compr Canc Netw 2021;19:267\u2013274."},{"key":"B51","series-title":"N Engl J Med","first-page":"538","article-title":"Frailty in older adults","volume":"391","author":"Kim DH","year":"2024","unstructured":"Kim DH, Rockwood K. Frailty in older adults. N Engl J Med 2024;391:538\u2013548."},{"key":"B52","series-title":"BMC Geriatr","first-page":"557.","article-title":"Polypharmacy and drug interactions in older patients with cancer receiving chemotherapy: associated factors","volume":"24","author":"Oliveira RF","year":"2024","unstructured":"Oliveira RF, Oliveira AI, Cruz AS,  Polypharmacy and drug interactions in older patients with cancer receiving chemotherapy: associated factors. BMC Geriatr 2024;24:557."},{"key":"B53","series-title":"Oncologist","first-page":"e502","article-title":"Polypharmacy, inappropriate medication use, and drug interactions in older Korean patients with cancer receiving first-line palliative chemotherapy","volume":"25","author":"Hong S","year":"2020","unstructured":"Hong S, Lee JH, Chun EK,  Polypharmacy, inappropriate medication use, and drug interactions in older Korean patients with cancer receiving first-line palliative chemotherapy. Oncologist 2020;25:e502\u2013511."},{"key":"B54","series-title":"J Geriatr Oncol","first-page":"593","article-title":"The influence of polypharmacy, potentially inappropriate medications, and drug interactions on treatment completion and prognosis in older patients with ovarian cancer","volume":"11","author":"J\u00f8rgensen TL","year":"2020","unstructured":"J\u00f8rgensen TL, Herrstedt J. The influence of polypharmacy, potentially inappropriate medications, and drug interactions on treatment completion and prognosis in older patients with ovarian cancer. J Geriatr Oncol 2020;11:593\u2013602."},{"key":"B55","series-title":"Oncologist","first-page":"e968","article-title":"Adverse drug reactions in an oncological population: prevalence, predictability, and preventability","volume":"24","author":"Lavan AH","year":"2019","unstructured":"Lavan AH, O\u2019Mahony D, Buckley M,  Adverse drug reactions in an oncological population: prevalence, predictability, and preventability.  Oncologist 2019;24:e968\u2013977."},{"key":"B56","series-title":"Pharmacoepidemiol Drug Saf","first-page":"728","article-title":"Association of potentially inappropriate medication use with patient and prescriber characteristics in Medicare Part D","volume":"22","author":"Holmes HM","year":"2013","unstructured":"Holmes HM, Luo R, Kuo YF,  Association of potentially inappropriate medication use with patient and prescriber characteristics in Medicare Part D. Pharmacoepidemiol Drug Saf 2013;22:728\u2013734."},{"key":"B57","series-title":"Ann Palliat Med","first-page":"542","article-title":"Combining opioids and benzodiazepines: effects on mortality and severe adverse respiratory events","volume":"9","author":"Boon M","year":"2020","unstructured":"Boon M, van Dorp E, Broens S,  Combining opioids and benzodiazepines: effects on mortality and severe adverse respiratory events. Ann Palliat Med 2020;9:542\u2013557."},{"key":"B58","series-title":"Clin Cancer Res","first-page":"2580","article-title":"Corticosteroids and cancer immunotherapy","volume":"29","author":"Goodman RS","year":"2023","unstructured":"Goodman RS, Johnson DB, Balko JM. Corticosteroids and cancer immunotherapy. Clin Cancer Res 2023;29:2580\u20132587."},{"key":"B59","series-title":"Lancet","first-page":"1894","article-title":"Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study","volume":"398","author":"Mohile SG","year":"2021","unstructured":"Mohile SG, Mohamed MR, Xu H,  Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet 2021;398:1894\u20131904."},{"key":"B60","article-title":"Presentation of a Geriatric Oncology Dashboard displaying the VA - Frailty Index and Recommendations for use in the Oncology Applications (OncApps) Platform at the Department of Veterans Affairs","author":"Elbers DC","unstructured":"Elbers DC, DuMontier C, Tarren A. Presentation of a Geriatric Oncology Dashboard displaying the VA - Frailty Index and Recommendations for use in the Oncology Applications (OncApps) Platform at the Department of Veterans Affairs. Presented at the AMIA 2023 Annual Symposium; November 11\u201315, 2023; New Orleans, Louisianna."},{"key":"B61","article-title":"The QUERI Roadmap for Implementation and Quality Improvement","author":"Goodrich DE","year":"2020","unstructured":"Goodrich DE, Miake-Lye I, Braganza MZ,  The QUERI Roadmap for Implementation and Quality Improvement. Department of Veterans Affairs; 2020."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/9\/article-p363.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/9\/article-p363.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/9\/article-p363.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T12:25:39Z","timestamp":1757507139000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/9\/article-p363.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":61,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7051","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}